| DIRECT COMPETITOR COMPARISON | |
| ALKS | BMY | FRX | JNJ | Industry | | Market Cap: | 817.82M | 50.28B | 9.22B | 173.52B | 73.54M | | Employees: | 570 | 35,000 | 5,225 | 118,700 | 43 | | Qtrly Rev Growth (yoy): | 1.80% | 4.40% | 4.20% | -5.30% | 3.00% | | Revenue (ttm): | 295.19M | 21.14B | 3.93B | 60.53B | 17.49M | | Gross Margin (ttm): | 84.83% | 72.39% | 78.33% | 71.08% | 63.53% | | EBITDA (ttm): | 116.61M | 6.32B | 881.14M | 19.05B | -6.12M | | Oper Margins (ttm): | 32.44% | 26.65% | 20.40% | 26.94% | -3.79% | | Net Income (ttm): | 80.25M | 3.79B | 730.30M | 12.77B | N/A | | EPS (ttm): | 0.842 | 1.933 | 2.414 | 4.579 | -0.19 | | P/E (ttm): | 10.25 | 13.13 | 12.66 | 13.73 | 15.52 | | PEG (5 yr expected): | N/A | 2.51 | 1.98 | 1.85 | 1.32 | | P/S (ttm): | 2.86 | 2.40 | 2.39 | 2.89 | 3.27 |
|
| BMY = Bristol-Myers Squibb Co. | | FRX = Forest Laboratories Inc. | | JNJ = Johnson & Johnson | | Industry = Drug Delivery | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.21 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
|
|
|